This refresh
Data-driven refresh July 14, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,237 tickers); 1,780 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90.1
Health Information Services · price $21.80 · 1Y $24.53 · 5Y $35.91 · 10Y $53.27
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 22.2x B+ · PEG 0.59 A-
Why now. DOCS is set to dominate the U.S. physician digital workflow thanks to its AI‑driven Ask assistant, which embeds evidence‑based content directly into clinicians’ daily routines. That stickiness fuels a 13.1% YoY revenue growth, while a 30.4% profit margin and a PEG of 0.59 prove the business is scaling profitably and at a discount to peers. The thesis rests on the compounding loop of more doctors joining the platform, generating more data, which powers a better AI experience and higher ad‑sponsored revenue.
Moat. DOCS’ moat is its physician‑only network and the HIPAA‑compliant workflow tools (Ask, Scribe) that become irreplaceable once integrated into clinical practice, creating high switching costs. The 20.6% ROE stems from pricing power in a category‑lead position where health systems pay premium rates to reach a captive audience of U.S. doctors, a barrier hard for generic platforms to breach.
Risk. The stock trades at a 22.2× forward P/E despite a modest 13% growth rate, suggesting the market may be over‑paying if revenue acceleration stalls. A beta of 1.29 adds market‑risk volatility, and the 52‑week high of $76.51 versus today’s $21.80 shows the price is still far from its historic peak, indicating limited upside if growth decelerates. A breach of the 52‑week low ($17.15) would confirm the bear case and force a re‑rating.
Horizon. 1-3 yr $24.53 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $35.91 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $53.27 if current growth sustains into durable earnings power.
2. ADBE — Adobe Inc. · score 89.6
Software - Application · price $220.78 · 1Y $272.48 · 5Y $398.93 · 10Y $591.79
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 12.6x A · PEG 0.61 A-
Why now. Adobe's market-leading position in both its Digital Media and Digital Experience segments is generating substantial cash flow, making its current valuation deeply compelling. A P/E of 12.6 and a PEG ratio of 0.61 are exceptionally low for a company with a robust 11.5% FY YoY revenue growth, indicating significant undervaluation. The crux of the thesis is that this cash-generative growth, evidenced by $10.3B in TTM free cash flow, will continue to compound shareholder value as the market re-rates its multiple.
Moat. Adobe's formidable moat stems from the deeply embedded nature of its Digital Media products, which serve as industry-standard tools for professionals across photography, video editing, and graphic design, creating high switching costs. This category leadership, combined with its Digital Experience segment's integrated platform for brands, underpins an exceptional ROE of 62.8%, reflecting strong pricing power and efficient capital utilization. The company's intellectual property and ecosystem lock-in make it incredibly difficult for competitors to replicate its comprehensive offerings.
Risk. The bear case argues that Adobe's growth, while solid at 11.5% FY YoY revenue growth, is vulnerable to increased competition in both content creation and customer experience platforms, potentially leading to margin pressure. The stock's high beta of 1.43 indicates sensitivity to broader market downturns, which could exacerbate any perceived slowdown in its core Digital Media and Digital Experience segments. A sustained decline in new subscriber additions or enterprise software spending, leading to further margin compression from the current 28.7% profit margin, would confirm the bear thesis.
Horizon. 1-3 yr $272.48 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $398.93 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $591.79 if current growth sustains into durable earnings power.
3. INTU — Intuit Inc. · score 89.1
Software - Application · price $282.43 · 1Y $480.68 · 5Y $703.76 · 10Y $1,044
FCF $7.8b B+ · Rev +15.1% B+ · D/E 0.33 B · P/E 17.2x A- · PEG 0.71 A-
Why now. Intuit’s QuickBooks Online platform is the undisputed accounting backbone for the $5 trillion SMB market, and its subscription base is expanding at 15.1% YoY revenue growth while delivering a 21.9% profit margin and a PE of 17.2x, well below the sector premium. The combination of sticky SaaS revenue, high‑margin payroll and financing add‑ons, and a 22.2% ROE means earnings will compound as the SMB ecosystem deepens, making the current price a launchpad for multi‑year outperformance.
Moat. QuickBooks and Mailchimp lock small‑ and mid‑market firms into an integrated ecosystem of accounting, payroll, payments and marketing, creating high switching costs and cross‑sell leverage. The 22.2% ROE stems from pricing power in a category where Intuit is the default solution, and its $7.8 B free cash flow lets it reinvest in product innovation faster than any challenger can match.
Risk. The primary threat is a wave of low‑cost, cloud‑native competitors eroding QuickBooks’ pricing power, especially as the PE of 17.2x suggests the market already rewards growth; a slowdown to sub‑10% revenue growth would compress margins and push the PE toward sector averages, triggering a sell‑off. A sustained dip in free cash flow below $5 B would confirm the bear case.
Horizon. 1-3 yr $480.68 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $703.76 at ~20% CAGR — compounding case rests on the competitive position widening. 10 yr $1,044 if current growth sustains into durable earnings power.
4. DLO — DLocal Limited · score 89
Software - Infrastructure · price $14.84 · 1Y $17.85 · 5Y $26.13 · 10Y $38.77
FCF $413m C · Rev +46.6% A · D/E 0.20 B+ · P/E 23.2x B+ · PEG 0.50 A
Why now. DLocal’s cross‑border pay‑in platform for e‑commerce, ride‑hailing and streaming merchants is the engine of relentless top‑line expansion, delivering 46.6% YoY revenue growth while converting that scale into a 34.6% ROE and a cheap PEG of 0.5. The combination of a 23.2× P/E on fast‑growing cash‑generating earnings and $413 m of free cash flow gives the stock a high‑quality growth profile that will compound as global merchants deepen their reliance on DLocal’s multi‑APM payment suite. The thesis hinges on the continued secular shift to digital payments in emerging markets, which fuels the same compounding loop.
Moat. DLocal’s pay‑in suite locks merchants into a single integration that supports hundreds of local cards, bank transfers and alternative payment methods, creating high switching costs and network effects across its platform. Its “dLocal for Platforms” product deepens relationships with large ecosystem players, allowing the firm to capture pricing power that drives the 34.6% ROE, a margin advantage hard for new entrants to replicate quickly.
Risk. The stock trades at a premium P/E of 23.2 despite a 46.6% growth rate, meaning any slowdown in merchant adoption or a dip in margin would force a sharp re‑rating; bears point to the 52‑week low of $9.81 and the analyst target range bottom of $14.5 as evidence of downside risk. A deceleration of revenue growth below 30% would validate the valuation concern and push the price toward that lower bound.
Horizon. 1-3 yr $17.85 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $26.13 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $38.77 if current growth sustains into durable earnings power.
5. NBIX — Neurocrine Biosciences, Inc. · score 87.1
Drug Manufacturers - Specialty & Generic · price $172.04 · 1Y $199.27 · 5Y $291.76 · 10Y $432.80
FCF $831m C+ · Rev +28.6% A- · D/E 0.14 B+ · P/E 26.5x B · PEG 0.50 A
Why now. Neurocrine Biosciences is a compelling growth story, trading at an attractive valuation given its robust top-line expansion and profitability. With revenue growth at 28.6% (FY YoY) and a strong profit margin of 21.6%, the company is efficiently converting sales into earnings, reflected in its exceptionally low PEG ratio of 0.5. The sustained demand for products like INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, alongside a promising pipeline, underpins this compounding growth.
Moat. Neurocrine's durable edge stems from its specialized focus on discovering, developing, and commercializing pharmaceuticals for complex neurological, psychiatric, endocrine, and immunological disorders. The success of products like INGREZZA, protected by intellectual property, creates significant barriers to entry for competitors due to the high costs and lengthy timelines associated with drug development and regulatory approval in these therapeutic areas. This specialized expertise and established product portfolio contribute to the company's strong ROE of 19.6%.
Risk. The primary bear case for Neurocrine centers on the inherent risks of pharmaceutical development and commercialization, particularly the potential for pipeline failures or increased competition for its key products. While current growth is strong, a significant setback in clinical development for candidates like NBI-1076986 or Osavampator, or an unexpected challenge to the market position of INGREZZA, could severely impact future revenue streams. The current P/E TTM of 26.5, while reasonable for its growth, still prices in continued success, making the stock vulnerable to any signs of decelerating growth or increased R&D costs.
Horizon. 1-3 yr $199.27 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $291.76 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $432.80 if current growth sustains into durable earnings power.
6. LRN — Stride, Inc. · score 86.9
Education & Training Services · price $86.88 · 1Y $99.91 · 5Y $146.28 · 10Y $217.00
FCF $414m C · Rev +10.9% B · D/E 0.33 A- · P/E 13.6x A- · PEG 0.51 A-
Why now. Stride’s end‑to‑end virtual‑school platform is locking in multi‑year contracts with public districts, creating a sticky revenue base that compounds at 10.9% revenue growth while delivering 12.2% profit margins and a PEG of 0.51. The low‑beta, high‑ROE model means earnings can be reinvested at a near‑20% return, fueling continued expansion in the booming blended‑learning market. The thesis hinges on the platform’s ability to keep scaling contracts as districts shift to hybrid instruction.
Moat. The integrated suite of curriculum, enrollment, progress‑tracking and support services creates high switching costs for school districts that have built entire virtual‑school operations on Stride’s technology, making it difficult for competitors to replicate the data‑rich, turnkey solution. This stickiness underpins the 18.8% ROE, which stems from pricing power in a niche where districts value a single‑vendor ecosystem.
Risk. The bear case focuses on the slowdown risk: revenue growth has slowed to just 10.9% YoY and the stock trades at a modest P/E of 13.6 despite a 52‑week high of $171.17, indicating market skepticism about sustained growth. A contraction in public‑sector funding or a loss of a few large district contracts would compress margins and could push the price back toward the 52‑week low of $60.61. Confirmation would be a quarterly revenue growth dip below 5% and a widening debt‑to‑equity ratio.
Horizon. 1-3 yr $99.91 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $146.28 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $217.00 if current growth sustains into durable earnings power.
7. NVDA — NVIDIA Corporation · score 85.7
Semiconductors · price $211.80 · 1Y $301.62 · 5Y $441.60 · 10Y $655.09
FCF $119.1b A · Rev +70.7% A · D/E 0.07 A- · P/E 32.4x B · PEG 0.65 A-
Why now. NVIDIA's Compute & Networking segment is locked into the exploding AI infrastructure wave, with its data‑center accelerated computing platforms now powering the majority of enterprise AI workloads. The business is growing revenue at an eye‑popping 70.7% YoY, while delivering a 63% profit margin and a staggering 81.7% ROE, proving it can turn scale into cash. This compounding engine will keep the AI spend tailwind alive, making the stock a pure growth play.
Moat. The moat lives in NVIDIA's GPU architecture dominance in the data‑center segment, where customers face massive switching costs to re‑tool software stacks for any rival chip. Its pricing power stems from being the de‑facto standard for AI acceleration, allowing it to sustain a 63% margin and generate $119.1 billion of free cash flow, which funds relentless R&D and entrenches its lead.
Risk. The biggest headwind is valuation: a forward P/E of 32.4 is high for a megacap, and any slowdown in AI spend could compress margins, especially given the stock's beta of 2.21. A pull‑back in data‑center demand that trims revenue growth below 50% would force the price toward the 52‑week low of $164.07, confirming the bear case.
Horizon. 1-3 yr $301.62 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $441.60 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $655.09 if current growth sustains into durable earnings power.
8. EXLS — ExlService Holdings, Inc. · score 85.5
Information Technology Services · price $27.32 · 1Y $40.13 · 5Y $58.75 · 10Y $87.15
FCF $297m C · Rev +13.4% B+ · D/E 0.67 C+ · P/E 17.4x A- · PEG 0.91 B+
Why now. EXLS is poised to dominate AI‑driven digital operations in the insurance segment, where its claims‑management and underwriting analytics platform locks in long‑term contracts. The business is already delivering 13.4% revenue growth, 11.7% profit margin and a stellar 32.3% ROE, while trading at a sub‑1.0 PEG of 0.91, meaning earnings are compounding faster than the market expects. The thesis rests on the relentless expansion of AI‑enabled insurance workflows that generate sticky, high‑margin cash flows for the next decade.
Moat. EXLS’s moat comes from its proprietary AI analytics engine embedded in insurance, healthcare and banking workflows, creating high switching costs for carriers that rely on its claims‑management and actuarial platforms. That stickiness fuels the 32.3% ROE, driven by pricing power in a niche where regulators and legacy systems make rapid replication difficult.
Risk. The bear case hinges on a valuation premium: a forward P/E of 17.4 is lofty for a 13.4% growth rate, and a debt‑to‑equity of 0.67 adds leverage risk if AI spend cycles cool. A slowdown to sub‑10% YoY revenue growth would validate the overvaluation argument and trigger a price correction.
Horizon. 1-3 yr $40.13 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $58.75 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $87.15 if current growth sustains into durable earnings power.
9. HRMY — Harmony Biosciences Holdings, Inc. · score 85.3
Biotechnology · price $34.81 · 1Y $44.91 · 5Y $65.75 · 10Y $97.54
FCF $342m C · Rev +20.7% A- · D/E 0.18 B+ · P/E 14.0x A- · PEG 0.65 A-
Why now. Harmony Biosciences presents an attractive growth opportunity trading at a discount, driven by the continued expansion of WAKIX in narcolepsy and a promising pipeline for rare neurological diseases. The company boasts impressive 20.7% FY YoY revenue growth, a compelling PEG ratio of 0.65, and robust $342m in TTM free cash flow, indicating strong operational efficiency for its $2.0b market cap. The thesis rests on the sustained market penetration of WAKIX and the successful clinical progression of Pitolisant into new indications like Prader-Willi Syndrome.
Moat. Harmony's durable edge stems from WAKIX (pitolisant)'s novel mechanism of action for excessive daytime sleepiness in narcolepsy, providing significant intellectual property protection and differentiation in a specialized market. The company's focused expertise in developing therapies for rare neurological diseases, further evidenced by Pitolisant's pipeline expansion into Prader-Willi Syndrome and Myotonic Dystrophy, creates high switching costs for patients and prescribers. A low debt-to-equity ratio of 0.18 provides financial flexibility to continue investing in its specialized R&D efforts and commercialization infrastructure.
Risk. The primary bear case centers on the significant clinical trial risk inherent in pharmaceutical development, particularly for Pitolisant's ongoing Phase 3 trial for Prader-Willi Syndrome and Phase 2 trials for Myotonic Dystrophy. Failure in these pivotal trials would severely curtail future growth prospects, especially as the current price of 34.81 sits near its 52-week high of 40.87, offering limited downside protection. The wide analyst target range of $28–$85 highlights the market's substantial uncertainty regarding the success of these pipeline catalysts, with the low end suggesting significant downside. A concrete signal confirming the bear case would be a negative outcome from the Phase 3 PWS trial.
Horizon. 1-3 yr $44.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $65.75 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $97.54 if current growth sustains into durable earnings power.
10. ADMA — ADMA Biologics, Inc. · score 84
Biotechnology · price $8.87 · 1Y $17.60 · 5Y $25.77 · 10Y $38.23
FCF $108m C · Rev +11.0% B · D/E 1.11 C · P/E 13.0x A · PEG 0.66 A-
Why now. ADMA’s BIVIGAM and ASCENIV IVIG franchise is poised to double earnings as the U.S. immune‑deficiency market expands, driven by its 32.4% profit margin, ultra‑low PEG of 0.66 and a PE of 13 that undervalues a 42.4% ROE business; the compounding engine is the growing demand for plasma‑derived therapies and ADMA’s ability to scale manufacturing, making the upside hinge on sustaining that margin and growth trajectory.
Moat. The company’s moat lies in its vertically integrated plasma collection and bio‑manufacturing network, which secures a steady supply of high‑quality plasma for BIVIGAM, ASCENIV and Nabi‑HB, creating switching costs for hospitals that rely on consistent product purity and FDA‑approved formulations—an advantage that fuels the 42.4% ROE by protecting pricing power in a niche, regulated market.
Risk. The bear case centers on the concentration risk of the IVIG market; a single competitor launching a lower‑cost biosimilar could compress margins, and ADMA’s debt‑to‑equity of 1.11 signals leverage that could strain cash flow if pricing pressure intensifies. A breach of the 32.4% margin or a widening of debt would validate the downside, likely pushing the stock back toward its 52‑week low of $7.21.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $25.77 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $38.23 if current growth sustains into durable earnings power.
11. CARG — CarGurus, Inc. · score 83.6
Auto & Truck Dealerships · price $34.05 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +14.0% B+ · D/E 0.79 B · P/E 17.9x B+ · PEG 1.04 B+
Why now. CarGurus' Digital Deal platform is turning its massive shopper audience into a high‑margin, recurring revenue engine, fueling 14% YoY revenue growth while delivering $293 m of free cash flow and an eye‑popping 62.9% ROE. The PEG of 1.04 shows the stock is fairly priced relative to its growth, and the consensus 1‑yr target of $37.38 already prices in near‑term upside. The thesis rests on the compounding power of Digital Deal expanding its dealer‑subscription base.
Moat. The integrated dealer‑subscription and advertising model locks dealers into CarGurus' ecosystem; once a dealer adopts Digital Deal, switching costs rise because listings, lead data, and financing partnerships are all tied to the platform. This network lock‑in underpins the 62.9% ROE, reflecting pricing power from being the go‑to marketplace for both shoppers and dealers.
Risk. A bear sees the growth engine stalling as competition intensifies and the 14% revenue growth slows, while the 0.79 debt‑to‑equity ratio and a beta of 1.18 amplify downside risk; the 17.9× P/E suggests the market may already be pricing in higher growth than is sustainable. A breach of the 52‑week low ($26.39) would confirm the growth slowdown and trigger a sell‑off.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
12. EPAM — EPAM Systems, Inc. · score 83.3
Information Technology Services · price $84.50 · 1Y $135.94 · 5Y $199.03 · 10Y $295.25
FCF $544m C+ · Rev +14.2% B+ · D/E 0.08 B+ · P/E 12.1x A · PEG 0.44 A
Why now. EPAM’s digital platform engineering and cloud services are the engine of enterprise digital transformation, and that spend is accelerating. The business is delivering 14.2% YoY revenue growth while trading at a rock‑bottom PE of 12.1x and a PEG of 0.44, meaning the market is severely under‑pricing its growth runway. Coupled with $544 m of free cash flow and a ultra‑low debt‑to‑equity of 0.08, the compounding engine of high‑margin services will keep cash generation and earnings expanding for years to come.
Moat. EPAM’s end‑to‑end engineering practice—from requirements analysis to smart automation—creates deep integration with Fortune‑500 clients, making migration to a rival provider costly and time‑consuming. Its platform‑centric model and cross‑industry AI/analytics capabilities lock in recurring revenue, while the low leverage (D/E 0.08) lets it reinvest cash without diluting shareholders, sustaining a ROE of 11.3% driven by pricing power in high‑value digital projects.
Risk. The stock’s beta of 1.43 makes it highly sensitive to market swings, and any slowdown in enterprise digital spend would crush the 14.2% growth rate that underpins the valuation. A miss on FY revenue growth falling below 10% YoY would signal margin pressure and justify the market’s 52‑week high of $222.53 being out of reach. A sustained dip in growth would force the PE to compress, confirming the bear case.
Horizon. 1-3 yr $135.94 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $199.03 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $295.25 if current growth sustains into durable earnings power.
13. RMD — ResMed Inc. · score 83.1
Medical Instruments & Supplies · price $193.01 · 1Y $253.73 · 5Y $371.49 · 10Y $551.08
FCF $1.8b C+ · Rev +10.3% B · D/E 0.13 B+ · P/E 18.6x A- · PEG 1.20 B+
Why now. ResMed's robust free cash flow generation of $1.8B on a $28.0B market cap (a 6.4% FCF yield) underscores its compounding power, driven by persistent demand for its Sleep and Breathing Health devices like ApneaLink Air and cloud-based software applications. With a healthy 27.4% profit margin and 10.3% revenue growth, the company is effectively translating its market leadership in respiratory disorder management into shareholder value. The crux lies in the expanding global need for diagnostics and treatment of sleep apnea, which ensures a long runway for its specialized medical devices and integrated software solutions.
Moat. ResMed's durable edge stems from its specialized intellectual property and integration of medical devices like NightOwl with cloud-based software applications for diagnosing and managing respiratory disorders. This creates significant switching costs for sleep clinics and hospitals, as their workflows become deeply embedded with ResMed's ecosystem. The company's impressive 23.4% Return on Equity is a direct result of its pricing power and category leadership in these critical, high-barrier-to-entry medical segments, making it difficult for new entrants to compete effectively.
Risk. The primary bear case for ResMed centers on increasing competitive pressure within the "Sleep and Breathing Health" segment, particularly from alternative diagnostic devices or treatment modalities that could erode its market share. The stock's significant drop from its 52-week high of $293.81 to the current $193.01 suggests investors are already pricing in some skepticism regarding future growth or margin sustainability. A sustained deceleration in its 10.3% revenue growth or a noticeable contraction in its 27.4% profit margin would confirm the bear thesis, indicating that its specialized devices are losing their pricing power or market penetration.
Horizon. 1-3 yr $253.73 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $371.49 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $551.08 if current growth sustains into durable earnings power.
14. IT — Gartner, Inc. · score 82.9
Information Technology Services · price $132.97 · 1Y $164.23 · 5Y $240.45 · 10Y $356.69
FCF $1.3b C+ · Rev +2.3% C · D/E n/a · P/E 13.1x A · PEG 0.54 A-
Why now. Gartner’s Insights subscription platform is a cash‑generating engine that compounds as executives renew access to its exclusive data, benchmarks and expert network, driving a durable earnings runway. The business trades at a modest PE of 13.1x and a razor‑thin PEG of 0.54, while delivering an 11.4% profit margin and $1.3 B of free cash flow, underscoring its ability to reinvest and buy back shares. The thesis rests on the relentless stickiness of its subscription base, which will keep compounding earnings at a steady clip.
Moat. The Insights segment locks clients into multi‑year contracts for proprietary research, data sets and direct access to Gartner’s analyst network, creating high switching costs and a barrier to new entrants. This subscription moat yields predictable cash flow and limits price competition, while the Conferences and Consulting arms reinforce the relationship ecosystem.
Risk. Revenue growth has stalled at just 2.3% YoY, signaling limited upside in a market where peers are expanding faster; any slowdown in subscription renewals would compress the already modest 11.4% margin. The consensus “hold” rating and a wide analyst target range ($120–$203) highlight uncertainty, and a breach of the 52‑week low ($124.25) would trigger a sell‑off, confirming the bear case.
Horizon. 1-3 yr $164.23 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $240.45 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $356.69 if current growth sustains into durable earnings power.
15. DXCM — DexCom, Inc. · score 82.5
Medical Devices · price $74.12 · 1Y $85.24 · 5Y $124.80 · 10Y $185.13
FCF $1.4b C+ · Rev +16.1% B+ · D/E 0.47 B · P/E 31.8x C+ · PEG 1.40 B
Why now. Dexcom’s G7 platform is now the growth engine that will keep the company compounding, as the next‑generation CGM captures both new Type 1 diabetics and the expanding pre‑diabetes market with Stelo. The business is already delivering 16.1% revenue growth YoY, 19.3% profit margin and a 31.5% ROE, giving it a PEG of just 1.4 and a valuation that still rewards further expansion. The thesis rests on the G7’s ability to lock in patients for years, turning each new user into a recurring cash‑flow stream.
Moat. Dexcom’s moat comes from its integrated CGM ecosystem – the G7 sensor, the Share remote‑monitoring service and the Follow app – which creates high switching costs for both patients and endocrinologists. The company’s patented sensor chemistry and FDA‑cleared algorithms give it a technology edge that competitors cannot replicate quickly, while the pricing power of a market‑leading device fuels the 31.5% ROE.
Risk. The bear case hinges on accelerating competition and a potential slowdown in G7 adoption, which would expose Dexcom’s lofty 31.8× P/E and high beta of 1.45. If revenue growth falls below the current 16% pace and margins compress, the stock could revert toward its 52‑week low. A clear signal would be a quarterly earnings miss on both top‑line and margin guidance.
Horizon. 1-3 yr $85.24 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $124.80 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $185.13 if current growth sustains into durable earnings power.
16. VEEV — Veeva Systems Inc. · score 82
Health Information Services · price $193.09 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.2% B+ · D/E 0.01 A- · P/E 34.2x C+ · PEG 0.86 B+
Why now. Veeva Systems is a compounding machine, leveraging its deeply embedded Veeva Commercial Cloud and Veeva Data Cloud solutions to dominate the life sciences software market. A compelling PEG ratio of 0.86 suggests the market undervalues its growth, while a robust 28.4% profit margin and 16.2% revenue growth underscore its operational efficiency and market leadership. The crux of the thesis rests on the indispensable nature of its specialized, compliant cloud software, ensuring persistent demand and recurring revenue streams from a critical, high-value customer base.
Moat. Veeva's moat is built on the high switching costs and deep specialization inherent in its cloud-based software tailored for the life sciences industry. Products like Veeva Vault CRM Suite and Veeva PromoMats become indispensable to pharmaceutical and biotechnology companies due to their compliance and workflow integration, making migration to alternatives prohibitively expensive and risky. This specialized focus, particularly in managing medical content and customer reference data via Veeva Medical and Veeva OpenData, creates a formidable barrier that generalist software providers cannot easily overcome.
Risk. The bear case hinges on Veeva's elevated valuation and its concentrated exposure to the cyclical R&D spending of the life sciences industry. A P/E TTM of 34.2 prices in continued strong growth, which could be challenged if competition intensifies in specific product areas like analytics platforms (Veeva Crossix) or if pharmaceutical and biotechnology companies tighten their IT budgets. The concrete signal confirming the bear case would be a material deceleration in revenue growth from the current 16.2% or a sustained erosion of its impressive 28.4% profit margin, indicating either market saturation or a loss of pricing power.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
17. CVSA — Covista Inc. · score 80
Education & Training Services · price $132.11 · 1Y $156.25 · 5Y $228.77 · 10Y $339.36
FCF $336m C · Rev +9.7% B · D/E 0.54 B+ · P/E 19.2x B · PEG 0.88 B+
Why now. Covista’s compounding engine is its accredited online health‑profession education pipeline—Chamberlain and Walden universities are scaling certificate enrollments faster than any traditional campus. That is reflected in 9.7% YoY revenue growth, a sub‑1 PEG of 0.88 indicating cheap growth, and a solid ROE of 17.2% that shows earnings are being reinvested efficiently. The thesis rests on the relentless demand for nursing and allied‑health credentials that will keep cash flow expanding.
Moat. The moat lives in the regulatory and credentialing lock‑in of its degree‑granting segments. Chamberlain and Walden’s accredited programs require federal approval and extensive faculty accreditation, creating high switching costs for students and employers who rely on recognized credentials—an advantage competitors can’t replicate quickly.
Risk. The bear case hinges on enrollment headwinds that would blunt growth; a slowdown would expose the modest P/E of 19.2 as still premium for a 9.7% growth rate and could strain the debt‑to‑equity of 0.54 if cash conversion falters. A quarterly enrollment decline of more than 5% YoY would trigger a sell‑off and invalidate the compounding narrative.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $228.77 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $339.36 if current growth sustains into durable earnings power.
18. PODD — Insulet Corporation · score 79.3
Medical Devices · price $159.12 · 1Y $236.83 · 5Y $346.75 · 10Y $514.38
FCF $416m C · Rev +31.9% A · D/E 0.78 C+ · P/E 37.2x C+ · PEG 1.42 B
Why now. The Omnipod 5 automated insulin delivery system is turning Insulet into a compounding growth engine, as the platform’s closed-loop algorithm locks in premium pricing and recurring pod sales. Revenue is exploding at 31.9% YoY, while the business still delivers a healthy 10.4% profit margin and a 23.2% ROE, proving the model scales profitably. The thesis rests on the continued rollout of Omnipod 5 and the stickiness of its subscription‑style pod replacements.
Moat. Insulet’s moat is the proprietary AID algorithm baked into the Omnipod pod, which requires a Bluetooth‑linked CGM and a dedicated pod‑exchange cycle—creating high switching costs for diabetics and clinicians. This IP, combined with a pricing premium that fuels a >20% ROE, cannot be duplicated quickly by rivals lacking an integrated hardware‑software‑service ecosystem.
Risk. The stock trades at a lofty PE of 37.2 and a debt‑to‑equity of 0.78, leaving little margin for a slowdown; a dip in revenue growth below the current 31.9% YoY would expose the valuation gap and trigger a sell‑off. A confirmed slowdown to sub‑20% growth would be the red flag that validates the bear case.
Horizon. 1-3 yr $236.83 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $346.75 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $514.38 if current growth sustains into durable earnings power.
19. MELI — MercadoLibre, Inc. · score 79.1
Internet Retail · price $1873.88 · 1Y $2,204 · 5Y $3,228 · 10Y $4,788
FCF $11.8b A- · Rev +36.4% A · D/E 1.70 C+ · P/E 49.4x D · PEG 1.14 B+
Why now. MercadoLibre’s compounding engine is the Mercado Pago fintech suite, which locks merchants and shoppers into a cash‑less ecosystem and fuels cross‑selling on the Marketplace. The platform is scaling at a 36.4% FY revenue growth rate while generating $11.8B of free cash flow and delivering a 26.4% ROE, proving the business can reinvest profitably. The thesis rests on the continued expansion of digital payments across Brazil, Mexico, Argentina and beyond, where network effects lock in users and lock up future revenue streams.
Moat. The moat comes from the tightly integrated Marketplace‑to‑Pago loop: sellers need Mercado Pago to accept payments, and buyers rely on Mercado Pago for seamless checkout, creating a two‑sided network that is costly to replicate. High ROE stems from pricing power in a category‑leading e‑commerce platform that also controls logistics via Mercado Envios, giving the company cost advantages and stickiness that competitors cannot match quickly.
Risk. The stock trades at a lofty P/E of 49.4 and a beta of 1.34, indicating both valuation premium and volatility; any slowdown in the 36% revenue growth trajectory or a widening of the 1.7 debt‑to‑equity ratio would pressure margins and erode the ROE advantage. A breach of the 52‑week low ($1,495) would signal that growth is faltering and could trigger a sell‑off, invalidating the bull case.
Horizon. 1-3 yr $2,204 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,228 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $4,788 if current growth sustains into durable earnings power.
20. DECK — Deckers Outdoor Corporation · score 78.3
Footwear & Accessories · price $106.60 · 1Y $127.81 · 5Y $187.13 · 10Y $277.59
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 15.2x B+ · PEG 1.32 B
Why now. The bull case hinges on HOKA’s premium performance‑footwear franchise accelerating compounding earnings as athletes and outdoor enthusiasts double‑down on high‑margin, high‑growth products. Revenue is expanding 9.8% YoY, fueling a 41% ROE that outpaces peers, while free cash flow of $1.1 B gives management ample runway for share‑buybacks and strategic brand investment. The thesis rests on the persistence of this brand‑led growth engine.
Moat. Deckers’ moat derives from category leadership in premium performance and lifestyle footwear—HOKA dominates the high‑end running segment and UGG commands premium pricing in the casual luxury space—creating pricing power that translates into a 41% ROE. Coupled with a low debt‑to‑equity of 0.15, the company can reinvest cash without financing constraints, a barrier competitors find hard to replicate quickly.
Risk. The bear case centers on a potential slowdown in discretionary spending that would blunt the 9.8% revenue growth, leaving the stock vulnerable at a forward P/E of 15.2 and a beta of 1.17, indicating sensitivity to market swings. A miss on growth would push the price toward the low end of the analyst range ($90), confirming the downside thesis.
Horizon. 1-3 yr $127.81 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $187.13 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $277.59 if current growth sustains into durable earnings power.
21. FIVE — Five Below, Inc. · score 78.3
Specialty Retail · price $193.11 · 1Y $260.33 · 5Y $381.15 · 10Y $565.42
FCF $505m C+ · Rev +25.9% A- · D/E 0.86 B · P/E 24.4x C+ · PEG 0.98 B+
Why now. Five Below's consistent expansion of its specialty value retail footprint, offering everything from novelty candy to personalized living space products, is driving exceptional top-line growth. With a robust 25.9% FY YoY revenue growth and a highly attractive 0.98 PEG ratio, the market is not fully appreciating the compounding power of this retailer's ability to capture discretionary spending across diverse categories. The crux is Five Below's proven model of delivering high-value, trend-right merchandise, which fuels both store traffic and a healthy 8.7% profit margin, ensuring sustained earnings expansion.
Moat. Five Below's durable edge stems from its unique position as a specialty value retailer, offering a vast assortment of "classic and novelty candy bars," "cozy loungewear," and "personalized living space products" at compelling price points. This focus allows it to achieve an impressive 19% ROE by efficiently turning over high-demand, low-cost inventory that appeals to a broad demographic seeking affordable essentials and trend-right items. Competitors struggle to replicate this specific mix of value and variety across such diverse product categories without sacrificing either margin or customer appeal.
Risk. The bear case for Five Below centers on its exposure to cyclical discretionary spending, particularly across its "party goods, decorations," and "novelty décor" segments, which are highly sensitive to economic downturns. While growth has been strong, the current 24.4 P/E multiple could quickly contract if revenue growth decelerates from its 25.9% pace, especially given the company's 1.0 beta. A sustained decline in same-store sales or a significant increase in inventory levels would confirm that consumers are pulling back on these non-essential purchases, breaking the bull thesis.
Horizon. 1-3 yr $260.33 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $381.15 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $565.42 if current growth sustains into durable earnings power.
22. APP — AppLovin Corporation · score 78.1
Advertising Agencies · price $448.98 · 1Y $654.60 · 5Y $958.40 · 10Y $1,422
FCF $4.4b B · Rev +66.4% A · D/E 1.63 C · P/E 39.0x C+ · PEG 1.39 B
Why now. AppLovin's growth engine is its MAX in‑app bidding platform, which monetizes publisher inventory at premium rates; the 66.4% YoY revenue surge shows the market is buying, the 64.3% profit margin proves the model scales profitably, and the $4.4 B free cash flow gives runway for reinvestment and buybacks. The thesis rests on the compounding power of AI‑driven real‑time auctions that lock in higher CPMs and lock in developers for the long haul.
Moat. MAX creates a two‑sided network: publishers feed inventory while developers chase the highest‑value bids, generating a switching cost because advertisers trust the AI‑optimized outcomes and publishers see no cheaper way to extract full value. This lock‑in, combined with the high 64.3% profit margin, gives AppLovin pricing power that rivals cannot replicate without building comparable data assets and real‑time infrastructure.
Risk. The biggest headwind is the elevated valuation— a P/E of 39 and a PEG of 1.39 imply the market expects sustained double‑digit growth; any slowdown from the current 66.4% revenue growth would trigger a sharp multiple contraction. A bear signal would be a dip below the 52‑week low of $343 or a widening of the analyst target range toward the lower bound, confirming growth fatigue.
Horizon. 1-3 yr $654.60 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $958.40 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $1,422 if current growth sustains into durable earnings power.
23. NFLX — Netflix, Inc. · score 78
Entertainment · price $73.53 · 1Y $112.17 · 5Y $164.23 · 10Y $243.62
FCF $11.9b A- · Rev +16.7% B+ · D/E 0.54 B · P/E 23.7x B · PEG 1.44 B
Why now. Netflix is a high-quality compounder, leveraging its global reach and diverse content library to drive consistent growth. The company's ability to generate significant free cash flow of $11.9b, coupled with an impressive 28.5% profit margin and robust 16.7% revenue growth, underscores its market dominance in streaming entertainment services. The thesis rests on Netflix's continued ability to scale its content offering (TV series, documentaries, feature films, games, live programming) and monetize its vast global subscriber base.
Moat. Netflix's durable edge stems from its unparalleled content library and global distribution network, creating a powerful network effect and high switching costs for members. Its ability to deliver a vast array of entertainment across various genres and languages to a host of internet-connected devices worldwide is difficult to replicate. The company's exceptional 43% Return on Equity reflects its pricing power and efficient capital allocation, allowing it to continually invest in exclusive programming and expand its global footprint, solidifying its leadership position.
Risk. The primary bear case against Netflix centers on intense competition within the entertainment services sector, which could pressure subscriber growth and content spending efficiency, especially given its high Beta of 1.52. While the PEG ratio of 1.44 isn't extreme, it suggests that future growth is largely priced in, and the stock's current price of $73.53, hovering near its 52-week low of $70.86, indicates market apprehension. A sustained deceleration in subscriber additions or a significant increase in content acquisition costs without proportional revenue gains would confirm the bear thesis.
Horizon. 1-3 yr $112.17 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $164.23 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $243.62 if current growth sustains into durable earnings power.
24. META — Meta Platforms, Inc. · score 77.9
Internet Content & Information · price $661.04 · 1Y $826.63 · 5Y $1,210 · 10Y $1,795
FCF $48.3b A · Rev +26.2% A- · D/E 0.36 B+ · P/E 24.0x B · PEG 0.97 B+
Why now. Meta’s Family of Apps (FoA) is on a compounding runway, delivering 26.2% YoY revenue growth while converting that into a 32.8% profit margin and a staggering 29% ROE, proving the platform can monetize its massive user base at ever‑higher returns. The free cash flow of $48.3B gives it the firepower to reinvest in AI‑driven ad products and expand Reality Labs without diluting shareholders. The thesis hinges on the FoA network effect persisting, letting Meta keep scaling margins and cash generation for the foreseeable decade.
Moat. Meta’s moat lives in the entrenched network effects of Facebook, Instagram and Messenger, where each additional user amplifies data assets and ad inventory, creating a self‑reinforcing loop competitors can’t replicate quickly. This data advantage fuels pricing power that underpins the 29% ROE, while the integrated ad ecosystem locks advertisers into a single, high‑reach platform across the Family of Apps.
Risk. The bear case points to a valuation premium: a forward P/E of 24 is high for a growth name, and a beta of 1.25 amplifies market volatility, meaning any slowdown in the 26.2% revenue growth or margin compression would pressure the stock sharply. A dip in profit margin below the current 32.8% or a rise in debt‑to‑equity above 0.36 would signal the earnings engine is faltering. Confirmation would be a quarterly miss on revenue growth paired with a widening margin gap.
Horizon. 1-3 yr $826.63 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $1,210 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $1,795 if current growth sustains into durable earnings power.
25. MU — Micron Technology, Inc. · score 76.6
Semiconductors · price $983.12 · 1Y $1,486 · 5Y $2,176 · 10Y $3,227
FCF $26.2b A · Rev +167.0% A · D/E 0.06 A- · P/E 22.2x B+ · PEG 0.14 A
Why now. Micron is a compounding powerhouse, capitalizing on the explosive demand for advanced memory solutions, particularly in its Cloud Memory Business Unit and through its high-bandwidth memory (HBM) offerings. With revenue growth soaring at 167% FY YoY and an exceptional 55.9% profit margin, the company is generating immense free cash flow of $26.2b TTM, indicating robust operational leverage. The thesis rests on the sustained, structural demand for high-performance memory and storage products, especially CXL-based memory and HBM, which are critical enablers for AI and data center infrastructure.
Moat. Micron's durable edge stems from its technological leadership and massive scale in designing and manufacturing complex memory products like high-bandwidth memory (HBM) and CXL-based memory. This specialized expertise and the immense capital investment required to produce these critical components create significant barriers to entry, allowing Micron to command pricing power. An exceptional 50.1% Return on Equity reflects this advantage, driven by its indispensable role in supplying cutting-edge memory to the Cloud Memory Business Unit and Core Data Center Business Unit.
Risk. The bear case hinges on the inherent cyclicality of the semiconductor industry, where periods of rapid expansion can quickly give way to oversupply and pricing pressure, particularly for dynamic random access memory components and NAND-based MCPs. Despite current robust growth, the company's P/E of 22.2 is susceptible to multiple compression if the 167% revenue growth rate proves unsustainable, while a Beta of 2.14 signals extreme volatility. A concrete signal confirming the bear case would be a material slowdown in demand from the Mobile and Client Business Unit or a significant decline in average selling prices for its core memory products, indicating a market rebalancing.
Horizon. 1-3 yr $1,486 (analyst consensus (n=42)) — fundamentals + valuation re-rating. 5 yr $2,176 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $3,227 if current growth sustains into durable earnings power.
26. YUMC — Yum China Holdings, Inc. · score 76.3
Restaurants · price $43.30 · 1Y $61.34 · 5Y $89.81 · 10Y $133.23
FCF $931m C+ · Rev +6.7% C+ · D/E 0.38 A- · P/E 16.6x B+ · PEG 1.08 B+
Why now. Restaurants · market cap $14.9b. Down 26% from 52-week high of $58.39 — deep drawdown territory. 21 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $61.34 (implying +42% upside).
Moat. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 98% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $61.34 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $89.81 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $133.23 if current growth sustains into durable earnings power.
27. FISV — Fiserv, Inc. · score 76
Sector n/a · price $49.54 · 1Y $67.56 · 5Y $85.29 · 10Y $109.38
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.4x A- · PEG 2.33 C
Why now. Sector n/a · market cap $26.4b. Down 71% from 52-week high of $168.02 — deep drawdown territory. 27 sell-side analysts rate this a Hold with a mean 1-yr target of $67.56 (implying +36% upside).
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 71% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $67.56 (analyst consensus (n=27)) — multiple re-rating thesis requires a catalyst. 5 yr $85.29 at ~11% CAGR — dividend + buyback compounding. 10 yr $109.38 if the moat survives secular pressure.
28. DEO — Diageo plc · score 75.8
Beverages - Wineries & Distilleries · price $80.94 · 1Y $101.14 · 5Y $148.08 · 10Y $219.67
FCF n/a · Rev +4.8% C+ · D/E 1.77 C · P/E 18.7x B+ · PEG 0.80 A-
Why now. Beverages - Wineries & Distilleries · market cap $45.0b. Down 30% from 52-week high of $116.41 — deep drawdown territory. PEG 0.80 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $101.14 (implying +25% upside).
Moat. Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Down 30% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Dividend payout 96% of earnings on a 4.0% yield — distribution coverage is thin; one earnings stumble could force a dividend cut.
Horizon. 1-3 yr $101.14 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $148.08 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $219.67 if current growth sustains into durable earnings power.
29. ULTA — Ulta Beauty, Inc. · score 75.2
Specialty Retail · price $469.12 · 1Y $623.58 · 5Y $912.99 · 10Y $1,354
FCF $1.1b C+ · Rev +11.3% B · D/E 0.89 B · P/E 17.6x B+ · PEG 1.63 C+
Why now. Specialty Retail · market cap $20.2b. Down 34% from 52-week high of $714.97 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $623.58 (implying +33% upside).
Moat. ROE 46% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 34% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $623.58 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $912.99 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $1,354 if current growth sustains into durable earnings power.
30. EME — EMCOR Group, Inc. · score 74.3
Engineering & Construction · price $774.74 · 1Y $1,000 · 5Y $1,263 · 10Y $1,619
FCF $1.1b C+ · Rev +18.3% B+ · D/E 0.13 A- · P/E 26.0x B · PEG 0.41 A
Why now. Engineering & Construction · market cap $34.5b. 19% off the 52-week high of $951.96. Revenue growing +18%, comfortably above the S&P median. PEG 0.41 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $1,000 (implying +29% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,000 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,263 at ~10% CAGR — dividend + buyback compounding. 10 yr $1,619 if the moat survives secular pressure.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.